Peptide stacks, graded on the combination rather than the parts
A stack is not the sum of its compounds. Two well-evidenced compounds administered together are a third thing that nobody has necessarily studied, and the grade on every card below describes the combination itself.
It is worth knowing how rarely that grade is high. Of the 11 stacks here, 1 carries human trial evidence for the pairing. The rest are built from what each compound did on its own, plus a mechanistic argument for putting them together, and this site will not present that as more than it is.
What the grade on a stack means
Start from the goal
Complexity counts compounds, not difficulty. Every additional compound is another vial, another reconstitution, another injection site and one more thing that cannot be attributed if something changes.
| If the goal is | Stack | Compounds | Complexity | Combination evidence |
|---|---|---|---|---|
| Soft-tissue and tendon repair | Wolverine Stack | BPC-157 + TB-500 | Low · 2 | D · Preclinical |
| Growth-hormone axis research | CJC-1295 + Ipamorelin | CJC-1295 (no DAC / Mod GRF 1-29) + Ipamorelin | Low · 2 | D · Preclinical |
| Body recomposition support | Recomp Stack | BPC-157 + CJC-1295 / Ipamorelin blend + AOD-9604 + GHK-Cu + DSIP | Higher · 5 | D · Preclinical |
| Soft-tissue repair with a dermal component | GLOW Stack | BPC-157 + TB-500 + GHK-Cu | Medium · 3 | D · Preclinical |
| Soft-tissue repair with an anti-inflammatory component | KLOW Stack | BPC-157 + TB-500 + GHK-Cu + KPV | Higher · 4 | D · Preclinical |
| Chronic weight management | CagriSema | Cagrilintide + Semaglutide | Low · 2 | A · Strong |
| Chronic weight management | Cagrilintide + Tirzepatide | Cagrilintide + Tirzepatide | Low · 2 | X · Insufficient / conflicting |
| Chronic weight management | Cagrilintide + Retatrutide | Retatrutide + Cagrilintide | Low · 2 | X · Insufficient / conflicting |
| Weight management with a mitochondrial component | Retatrutide + MOTS-c | Retatrutide + MOTS-c | Low · 2 | X · Insufficient / conflicting |
| Growth hormone axis support | Tesamorelin + Ipamorelin | Tesamorelin + Ipamorelin | Low · 2 | D · Preclinical |
| Anxiety and cognitive support | Russian Nootropic Stack | Semax + Selank | Low · 2 | X · Insufficient / conflicting |
Browse the stacks
Browse protocols
11 protocols, every one of them a real page. Nothing here is a placeholder.
Cognitive & focus
Nootropic and neuropeptide protocols.
Growth hormone axis
Secretagogues and releasing hormones acting on growth hormone.
CJC-1295 + Ipamorelin
CJC-1295 (no DAC / Mod GRF 1-29) + Ipamorelin
The standard evening pairing. Pharmacologically coherent, clinically unproven.
- Weeks
- 12
- Compounds
- 2
- Vials
- 6
- From
- $159.99
Recomp Stack
BPC-157 + CJC-1295 / Ipamorelin blend + AOD-9604 + GHK-Cu + DSIP
A phased 16-week peptide stack covering repair, GH axis, sleep and focus. Ten sticks a week, not thirty.
- Weeks
- 16
- Compounds
- 5
- Vials
- 28
- From
- $892.00
Tesamorelin + Ipamorelin
Tesamorelin + Ipamorelin
An approved drug paired with a compound the FDA has placed on its significant-safety-risk list.
- Weeks
- 12
- Compounds
- 2
- Vials
- 26
- From
- $1,024.00
Tissue repair & recovery
Soft tissue, tendon and injury protocols. Heavily used, thinly evidenced.
Wolverine Stack
BPC-157 + TB-500
The most-searched stack in this category, and the one with the least human evidence behind it.
- Weeks
- 8
- Compounds
- 2
- Vials
- 9
- From
- $282.00
GLOW Stack
BPC-157 + TB-500 + GHK-Cu
The Wolverine Stack with a copper peptide added for skin. Three compounds, no combination trial.
- Weeks
- 8
- Compounds
- 3
- Vials
- 13
- From
- $324.00
KLOW Stack
BPC-157 + TB-500 + GHK-Cu + KPV
GLOW plus KPV. The fourth compound is the one the FDA says has no human exposure data at all.
- Weeks
- 8
- Compounds
- 4
- Vials
- 19
- From
- $498.00
Weight & metabolic
Incretin agonists and metabolic compounds. The best-evidenced group on the site.
CagriSema
Cagrilintide + Semaglutide
The only stack on this site with phase 3 evidence behind the combination itself, not just its parts.
- Weeks
- 68
- Compounds
- 2
- Vials
- 60
- From
- $2,043.00
Cagrilintide + Tirzepatide
Cagrilintide + Tirzepatide
Two well-evidenced compounds, and a pairing nobody has ever tested in a human being.
- Weeks
- 16
- Compounds
- 2
- Vials
- 16
- From
- $744.00
Cagrilintide + Retatrutide
Retatrutide + Cagrilintide
An unapproved compound paired with an unapproved compound. No trial, no label, no precedent.
- Weeks
- 16
- Compounds
- 2
- Vials
- 10
- From
- $1,042.95
Retatrutide + MOTS-c
Retatrutide + MOTS-c
One compound with a published phase 2. One compound with no human dosing data of any kind.
- Weeks
- 12
- Compounds
- 2
- Vials
- 30
- From
- $1,105.05
Why stacks are graded lower than their compounds
Tirzepatide has a large approved trial programme. Cagrilintide has a phase 2 dose-finding study. Putting them in the same week is a pairing with no trial at all, and no amount of evidence about either compound alone changes that. This is the most common error in the category and it is usually made in good faith: the compounds are well studied, so the stack feels well studied.
The exception proves the point. CagriSema is graded A because REDEFINE 1 randomised 3,417 people to that exact pairing at those exact amounts for 68 weeks. That is what evidence for a combination looks like, and it is worth having one page on the site that shows what the others are being measured against.
The second thing a stack multiplies is cost. Every compound is a separate vial with its own minimum purchase, and a vial that cannot be finished before its reconstituted shelf life is still a vial you bought. The cost table on each page simulates that rather than dividing milligrams.